Skip to content
BCI.INTEL
NLINKN1 Chip+PRIME.StudySYNCRStentrode+$200M.SeriesDPRECNLayer 7+FDA.BrkthruPARAMArgo+$20M.SeriesBBLKRKNeuroport+40.ImplantsEMTIVMN8+$45M.SeriesBKRNLFlux+Non-invasiveNRBLEHalo+Consumer.BCINEURONeuroPace+RNS.SystemCOGNICognixion+ALS.TrialTRIALSActive12.ClinTrials
Terminal/Device DB/DOT Microstimulator
minimally-invasiveIDEinvestigational

DOT Microstimulator

Implant Type
minimally-invasive
Electrodes
1
Channels
1
FDA Status
IDE
Clinical Stage
FDA-authorized first clinical trial for treatment-resistant depression (April 2026)
Status
investigational
About

Motif Neurotech's DOT is a blueberry-sized (9mm wide), leadless, batteryless implantable brain stimulator placed in the skull during a 20-minute outpatient procedure without ever exposing or contacting the brain. Receives data and power wirelessly from an external cap-like device via patented magnetoelectric power transfer technology developed at Rice University. Provides cell-type specific stimulation and electrical recording to regulate brain-wide circuits. Multiple DOTs can be networked to span the cortical surface for bilateral or multi-region stimulation. First product targets treatment-resistant depression. Intraoperative human studies demonstrated safe and effective stimulation, with 30+ day large animal studies completed.

Target Conditions
treatment-resistant depressionbipolar disorderAlzheimer's diseasesubstance use disorder
Milestones
2022-01Motif Neurotech founded via Rice Biotech Launch Pad
2024-06$18.75M Series A closed
2025-01UK ARIA multimillion-dollar award for therapeutic BCI development
2025-06Intraoperative human validation published on medRxiv
2025-12Patient registry launched for treatment-resistant depression
2026-01Clinical trials expected to begin H1 2026
2026-04FDA authorizes first clinical trial of the therapeutic BCI for treatment-resistant depression
FDA Regulatory Pathway
Investigational Device Exemption (IDE)

An IDE permits a device to be used in a clinical study to collect safety and effectiveness data required for a PMA or 510(k) submission. IDE devices are not approved for commercial sale.

FDA Device Regulatory Guidance ↗